{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:10:58Z","timestamp":1783044658118,"version":"3.54.6"},"reference-count":135,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council (NHMRC)","doi-asserted-by":"publisher","award":["APP1132975"],"award-info":[{"award-number":["APP1132975"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council (NHMRC)","doi-asserted-by":"publisher","award":["APP1158748"],"award-info":[{"award-number":["APP1158748"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Group A Streptococcus (GAS), or Streptococcus pyogenes, is a gram-positive bacterium that extensively colonises within the human host. GAS is responsible for causing a range of human infections, such as pharyngitis, impetigo, scarlet fever, septicemia, and necrotising fasciitis. GAS pathogens have the potential to elicit fatal autoimmune sequelae diseases (including rheumatic fever and rheumatic heart diseases) due to recurrent GAS infections, leading to high morbidity and mortality of young children and the elderly worldwide. Antibiotic drugs are the primary method of controlling and treating the early stages of GAS infection; however, the recent identification of clinical GAS isolates with reduced sensitivity to penicillin-adjunctive antibiotics and increasing macrolide resistance is an increasing threat. Vaccination is credited as the most successful medical intervention against infectious diseases since it was discovered by Edward Jenner in 1796. Immunisation with an inactive\/live-attenuated whole pathogen or selective pathogen-derived antigens induces a potent adaptive immunity and protection against infectious diseases. Although no GAS vaccines have been approved for the market following more than 100 years of GAS vaccine development, the understanding of GAS pathogenesis and transmission has significantly increased, providing detailed insight into the primary pathogenic proteins, and enhancing GAS vaccine design. This review highlights recent advances in GAS vaccine development, providing detailed data from preclinical and clinical studies across the globe for potential GAS vaccine candidates. Furthermore, the challenges and future perspectives on the development of GAS vaccines are also described.<\/jats:p>","DOI":"10.3390\/vaccines12030272","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:26:59Z","timestamp":1709638019000},"page":"272","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Recent Scientific Advancements towards a Vaccine against Group A Streptococcus"],"prefix":"10.3390","volume":"12","author":[{"given":"Jingyi","family":"Fan","sequence":"first","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Toth","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia"},{"name":"Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia"},{"name":"School of Pharmacy, The University of Queensland, Woolloongabba, QLD 4102, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6424-7502","authenticated-orcid":false,"given":"Rachel J.","family":"Stephenson","sequence":"additional","affiliation":[{"name":"School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, QLD 4072, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"201991","DOI":"10.1098\/rsos.201991","article-title":"A brief review on Group A Streptococcus pathogenesis and vaccine development","volume":"8","author":"Castro","year":"2021","journal-title":"R. Soc. Open Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1111\/1469-0691.12134","article-title":"Updated model of Group A Streptococcus M proteins based on a comprehensive worldwide study","volume":"19","author":"McMillan","year":"2013","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41579-023-00865-7","article-title":"Pathogenesis, epidemiology and control of Group A Streptococcus infection","volume":"21","author":"Brouwer","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fieber, C., and Kovarik, P. (2014). Responses of innate immune cells to Group A Streptococcus. Front. Cell Infect. Microbiol., 4.","DOI":"10.3389\/fcimb.2014.00140"},{"key":"ref_5","unstructured":"Ferretti, J.J., Stevens, D.L., and Fischetti, V.A. (2016). Streptococcus Pyogenes: Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center."},{"key":"ref_6","unstructured":"Ferretti, J.J., Stevens, D.L., and Fischetti, V.A. (2016). Streptococcus Pyogenes: Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center."},{"key":"ref_7","unstructured":"Ferretti, J.J., Stevens, D.L., and Fischetti, V.A. (2022). Streptococcus Pyogenes: Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center. [2nd ed.]."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Avire, N.J., Whiley, H., and Ross, K. (2021). A Review of Streptococcus pyogenes: Public Health Risk Factors, Prevention and Control. Pathogens, 10.","DOI":"10.3390\/pathogens10020248"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lu, Q., Yu, D., and Yang, Y. (2023). Group A Streptococcus Is Still at Large. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072739"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13052-023-01494-9","article-title":"Invasive Group A streptococcal infections: Are we facing a new outbreak? A case series with the experience of a single tertiary center","volume":"49","author":"Garancini","year":"2023","journal-title":"Ital. J. Pediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2300427","DOI":"10.2807\/1560-7917.ES.2023.28.36.2300427","article-title":"Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1(UK) and diverse emm12 isolates, Portugal, September 2022 to May 2023","volume":"28","author":"Gouveia","year":"2023","journal-title":"Eurosurveillance"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100873","DOI":"10.1016\/j.lanwpc.2023.100873","article-title":"Increase in invasive group A streptococcal disease among Australian children coinciding with northern hemisphere surges","volume":"41","author":"Abo","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100597","DOI":"10.1016\/j.lanepe.2023.100597","article-title":"Increasing incidence and severity of invasive Group A streptococcal disease in Spanish children in 2019\u20132022","volume":"27","author":"Calvo","year":"2023","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpam.2017.02.002","article-title":"Guidelines for the secondary prevention of rheumatic heart disease: Endorsed by Saudi Pediatric Infectious Diseases Society (SPIDS)","volume":"4","author":"Shahid","year":"2017","journal-title":"Int. J. Pediatr. Adolesc. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.18773\/austprescr.2022.034","article-title":"Therapeutics for rheumatic fever and rheumatic heart disease","volume":"45","author":"Ralph","year":"2022","journal-title":"Aust. Prescr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/CMR.00101-13","article-title":"Disease manifestations and pathogenic mechanisms of Group A Streptococcus","volume":"27","author":"Walker","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Azuar, A., Jin, W., Mukaida, S., Hussein, W.M., Toth, I., and Skwarczynski, M. (2019). Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems against Group A Streptococcus. Vaccines, 7.","DOI":"10.3390\/vaccines7030058"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/CMR.13.3.470","article-title":"Pathogenesis of group A streptococcal infections","volume":"13","author":"Cunningham","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/clinids\/14.1.2","article-title":"Invasive group A streptococcus infections","volume":"14","author":"Stevens","year":"1992","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.jinf.2014.08.005","article-title":"Management of invasive group A streptococcal infections","volume":"69","author":"Waddington","year":"2014","journal-title":"J. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","article-title":"The global burden of group A streptococcal diseases","volume":"5","author":"Carapetis","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijcard.2023.04.060","article-title":"Spatiotemporal trends in global burden of rheumatic heart disease and associated risk factors from 1990 to 2019","volume":"384","author":"Zhang","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13075-022-02829-3","article-title":"Global burden of rheumatic heart disease: Trends from 1990 to 2019","volume":"24","author":"Ou","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_24","unstructured":"(2016). Acute rheumatic fever and rheumatic heart disease. Nat. Rev. Dis. Primers, 2, 15085."},{"key":"ref_25","first-page":"31","article-title":"Rheumatic fever-identification, management and secondary prevention","volume":"41","author":"Smith","year":"2012","journal-title":"Aust. Fam. Physician"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/jpc.16305","article-title":"Acute rheumatic fever and rheumatic heart disease in children and adolescents in Victoria, Australia","volume":"59","author":"Lindholm","year":"2023","journal-title":"J. Paediatr. Child Health"},{"key":"ref_27","unstructured":"Welfare, A.I.o.H.a. (2023). Acute Rheumatic Fever and Rheumatic Heart Disease in Australia 2017\u20132021, Australian Institute of Health and Welfare."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jpids\/piad080","article-title":"Outbreak of invasive Group A Streptococcus in children\u2014Colorado, October 2022\u2013April 2023","volume":"12","author":"Ho","year":"2023","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101071","DOI":"10.1016\/j.nmni.2022.101071","article-title":"Group A streptococcal (GAS) infections amongst children in Europe: Taming the rising tide","volume":"51","author":"Jain","year":"2023","journal-title":"New Microbes New Infect."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2352-4642(22)00374-1","article-title":"Paediatric group A streptococcal disease in England from October to December, 2022","volume":"7","author":"Ladhani","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-0-387-73960-1_3","article-title":"Pathogenesis of group A streptococcal infections and their sequelae","volume":"609","author":"Cunningham","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_32","unstructured":"Baron, S. (1998). Medical Microbiology, University of Texas Medical Branch at Galveston. [4th ed.]."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4161\/viru.2.5.16342","article-title":"The M protein of Group A Streptococcus is a key virulence factor and a clinically relevant strain identification marker","volume":"2","author":"Metzgar","year":"2011","journal-title":"Virulence"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.47.1.91","article-title":"The antigenic complex of Streptococcus hemolyticus. I. Demonstration of a type-specific sub stance in extracts of Streptococcus hemolyticus","volume":"47","author":"Lancefield","year":"1928","journal-title":"J. Exp. Med."},{"key":"ref_35","unstructured":"Stevens, D.L., and Bryant, A.E. (2011). Tropical Infectious Diseases: Principles, Pathogens and Practice, Oxford University Press. [3rd ed.]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e00792-17","DOI":"10.1128\/IAI.00792-17","article-title":"Identification and Characterization of Serotype-Specific Variation in Group A Streptococcus Pilus Expression","volume":"86","author":"Calfee","year":"2018","journal-title":"Infect. Immun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3201\/eid2304.160773","article-title":"Incidence and Characteristics of Scarlet Fever, South Korea, 2008\u20132015","volume":"23","author":"Park","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1179\/2295333715Y.0000000066","article-title":"Group A streptococcal meningitis: Emm type distribution and theoretical vaccine coverage in children","volume":"71","author":"Tuerlinckx","year":"2016","journal-title":"Acta Clin. Belg."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1128\/JCM.01312-09","article-title":"Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: Emm types, multilocus sequence types, and superantigen profiles","volume":"48","author":"Meisal","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0966-842X(02)02461-7","article-title":"The fundamental contribution of phages to GAS evolution, genome diversification and strain emergence","volume":"10","author":"Banks","year":"2002","journal-title":"Trends Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.4269\/ajtmh.18-0827","article-title":"Systematic Review of Group A Streptococcal emm Types Associated with Acute Post-Streptococcal Glomerulonephritis","volume":"100","author":"Worthing","year":"2019","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM199109123251106","article-title":"Group A streptococcal infections and acute rheumatic fever","volume":"325","author":"Bisno","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1086\/499812","article-title":"Temporal changes in streptococcal M protein types and the near-disappearance of acute rheumatic fever in the United States","volume":"42","author":"Shulman","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1128\/JCM.43.9.4369-4376.2005","article-title":"M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns","volume":"43","author":"Tewodros","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1128\/JCM.40.12.4466-4471.2002","article-title":"M types of group a streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999","volume":"40","author":"Tyrrell","year":"2002","journal-title":"J. Clin. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4668","DOI":"10.1073\/pnas.062526099","article-title":"Genome sequence and comparative microarray analysis of serotype M18 Group A Streptococcus strains associated with acute rheumatic fever outbreaks","volume":"99","author":"Smoot","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1172\/JCI17247","article-title":"Rheumatic fever-associated Streptococcus pyogenes isolates aggregate collagen","volume":"111","author":"Dinkla","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4161\/hv.27332","article-title":"Recent progress in adjuvant discovery for peptide-based subunit vaccines","volume":"10","author":"Azmi","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7029","DOI":"10.1128\/IAI.69.11.7029-7038.2001","article-title":"Generation and surface localization of intact M protein in Streptococcus pyogenes are dependent on sagA","volume":"69","author":"Biswas","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zaman, M., Abdel-Aal, A.B., Fujita, Y., Phillipps, K.S., Batzloff, M.R., Good, M.F., and Toth, I. (2012). Immunological evaluation of lipopeptide Group A Streptococcus (GAS) vaccine: Structure-activity relationship. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030146"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"8317","DOI":"10.1073\/pnas.88.19.8317","article-title":"Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci","volume":"88","author":"Wessels","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1086\/529194","article-title":"The importance of the Group A Streptococcus capsule in the pathogenesis of human infections: A historical perspective","volume":"46","author":"Stollerman","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.175.5.1291","article-title":"Molecular characterization of a locus required for hyaluronic acid capsule production in group A streptococci","volume":"175","author":"Dougherty","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"28676","DOI":"10.1074\/jbc.270.48.28676","article-title":"Molecular characterization of hasC from an operon required for hyaluronic acid synthesis in group A streptococci. Demonstration of UDP-glucose pyrophosphorylase activity","volume":"270","author":"Crater","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"18452","DOI":"10.1074\/jbc.270.31.18452","article-title":"Hyaluronic acid synthesis operon (has) expression in group A streptococci","volume":"270","author":"Crater","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/414648a","article-title":"Group A Streptococcus tissue invasion by CD44-mediated cell signalling","volume":"414","author":"Cywes","year":"2001","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/infdis\/166.2.374","article-title":"Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis","volume":"166","author":"Johnson","year":"1992","journal-title":"J. Infect. Dis."},{"key":"ref_58","first-page":"707","article-title":"Antiphagocytic effect of the capsule of Streptococcus uberis","volume":"40","author":"Almeida","year":"1993","journal-title":"Zentralbl Vet. B"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1128\/IAI.02035-14","article-title":"Transcription of the Streptococcus pyogenes hyaluronic acid capsule biosynthesis operon is regulated by previously unknown upstream elements","volume":"82","author":"Falaleeva","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1128\/iai.65.1.64-71.1997","article-title":"Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the Group A Streptococcus","volume":"65","author":"Moses","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1111\/cmi.12531","article-title":"Streptococcal toxins: Role in pathogenesis and disease","volume":"17","author":"Barnett","year":"2015","journal-title":"Cell. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.GPP3-0054-2018","article-title":"Toxins and Superantigens of Group A Streptococci","volume":"7","author":"Shannon","year":"2019","journal-title":"Microbiol. Spectr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2958.2005.04583.x","article-title":"Mutational analysis of the group A streptococcal operon encoding streptolysin S and its virulence role in invasive infection","volume":"56","author":"Datta","year":"2005","journal-title":"Mol. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Higashi, D.L., Biais, N., Donahue, D.L., Mayfield, J.A., Tessier, C.R., Rodriguez, K., Ashfeld, B.L., Luchetti, J., Ploplis, V.A., and Castellino, F.J. (2016). Activation of band 3 mediates Group A Streptococcus streptolysin S-based beta-haemolysis. Nat. Microbiol., 1.","DOI":"10.1038\/nmicrobiol.2015.4"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1074\/jbc.M110.171504","article-title":"Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier","volume":"286","author":"Sumitomo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/IAI.71.1.446-455.2003","article-title":"Cytotoxic effects of streptolysin o and streptolysin s enhance the virulence of poorly encapsulated group a streptococci","volume":"71","author":"Sierig","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0378-1097(99)00536-4","article-title":"Thiol-activated cytolysins: Structure, function and role in pathogenesis","volume":"182","author":"Billington","year":"2000","journal-title":"FEMS Microbiol. Lett."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1128\/IAI.68.11.6384-6390.2000","article-title":"Role of streptolysin O in a mouse model of invasive group A streptococcal disease","volume":"68","author":"Limbago","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1074\/jbc.M511674200","article-title":"Enhancement of streptolysin O activity and intrinsic cytotoxic effects of the group A streptococcal toxin, NAD-glycohydrolase","volume":"281","author":"Michos","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_70","unstructured":"Ferretti, J.J., Stevens, D.L., and Fischetti, V.A. (2022). Streptococcus Pyogenes: Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center. [2nd ed.]."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3181\/00379727-212-43996","article-title":"Superantigens: Structure and relevance to human disease","volume":"212","author":"Johnson","year":"1996","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1038\/s41467-020-18700-5","article-title":"Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes","volume":"11","author":"Brouwer","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1084\/jem.111.2.255","article-title":"Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins","volume":"111","author":"Watson","year":"1960","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1128\/IAI.71.6.2983-2992.2003","article-title":"Extracellular enzymes with immunomodulating activities: Variations on a theme in Streptococcus pyogenes","volume":"71","author":"Collin","year":"2003","journal-title":"Infect. Immun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1126\/science.281.5383.1662","article-title":"Crystal structure of the catalytic domain of human plasmin complexed with streptokinase","volume":"281","author":"Wang","year":"1998","journal-title":"Science"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1086\/377100","article-title":"Plasminogen enhances virulence of group A streptococci by streptokinase-dependent and streptokinase-independent mechanisms","volume":"188","author":"Khil","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1128\/IAI.00180-15","article-title":"Streptococcus pyogenes triggers activation of the human contact system by streptokinase","volume":"83","author":"Nitzsche","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1126\/science.1101245","article-title":"Plasminogen is a critical host pathogenicity factor for group A streptococcal infection","volume":"305","author":"Sun","year":"2004","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0929-6646(08)60112-6","article-title":"Effects of streptococcal pyrogenic exotoxin B on pathogenesis of Streptococcus pyogenes","volume":"107","author":"Wu","year":"2008","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"17336","DOI":"10.1074\/jbc.M209038200","article-title":"Maturation processing and characterization of streptopain","volume":"278","author":"Chen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/iai.64.2.503-510.1996","article-title":"C5a peptidase alters clearance and trafficking of group A streptococci by infected mice","volume":"64","author":"Ji","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8144","DOI":"10.1073\/pnas.82.23.8144","article-title":"Mechanism of action of the group A streptococcal C5a inactivator","volume":"82","author":"Wexler","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1128\/iai.60.12.5219-5223.1992","article-title":"Streptococcal C5a peptidase is a highly specific endopeptidase","volume":"60","author":"Cleary","year":"1992","journal-title":"Infect. Immun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1128\/iai.65.6.2080-2087.1997","article-title":"Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the Group A Streptococcus","volume":"65","author":"Ji","year":"1997","journal-title":"Infect. Immun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1086\/432485","article-title":"Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes","volume":"192","author":"Edwards","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Laukova, L., Konecna, B., Janovicova, L., Vlkova, B., and Celec, P. (2020). Deoxyribonucleases and Their Applications in Biomedicine. Biomolecules, 10.","DOI":"10.3390\/biom10071036"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1093\/emboj\/20.12.3046","article-title":"EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG","volume":"20","author":"Collin","year":"2001","journal-title":"EMBO J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1038\/s41467-022-35340-z","article-title":"Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS","volume":"13","author":"Sudol","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/IAI.68.5.2441-2448.2000","article-title":"Characterization of an isogenic mutant of Streptococcus pyogenes Manfredo lacking the ability to make streptococcal acid glycoprotein","volume":"68","author":"Degnan","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0928-8244(04)00003-3","article-title":"Immune response to superoxide dismutase in group A streptococcal infection","volume":"40","author":"McMillan","year":"2004","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Johnson, A.F., and LaRock, C.N. (2021). Antibiotic Treatment, Mechanisms for Failure, and Adjunctive Therapies for Infections by Group A Streptococcus. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.760255"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"282","DOI":"10.2174\/156720111795256192","article-title":"Peptide-based subunit nanovaccines","volume":"8","author":"Skwarczynski","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Bashiri, S., Koirala, P., Toth, I., and Skwarczynski, M. (2020). Carbohydrate Immune Adjuvants in Subunit Vaccines. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12100965"},{"key":"ref_94","unstructured":"Ferretti, J.J., Stevens, D.L., and Fischetti, V.A. (2016). Streptococcus pyogenes: Basic Biology to Clinical Manifestations, University of Oklahoma Health Sciences Center."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1021\/acsinfecdis.0c00722","article-title":"Immunogenicity Assessment of Cell Wall Carbohydrates of Group A Streptococcus via Self-Adjuvanted Glyco-lipopeptides","volume":"7","author":"Khatun","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"02294","DOI":"10.1128\/mBio.02294-17","article-title":"Virulence Role of the GlcNAc Side Chain of the Lancefield Cell Wall Carbohydrate Antigen in Non-M1-Serotype Group A Streptococcus","volume":"9","author":"Henningham","year":"2018","journal-title":"mBio"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Fan, X., Wang, X., Li, N., Cui, H., Hou, B., Gao, B., Cleary, P.P., and Wang, B. (2014). Sortase A induces Th17-mediated and antibody-independent immunity to heterologous serotypes of group A streptococci. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0107638"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"42056","DOI":"10.1039\/C7RA07923K","article-title":"Mutagenesis and immunological evaluation of group A streptococcal C5a peptidase as an antigen for vaccine development and as a carrier protein for glycoconjugate vaccine design\u2020","volume":"7","author":"Li","year":"2017","journal-title":"RSC Adv."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"10226","DOI":"10.1073\/pnas.1700858114","article-title":"Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vbeta-specific T cells","volume":"114","author":"Zeppa","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1208\/s12248-017-0069-5","article-title":"Evaluation of the Potency, Neutralizing Antibody Response, and Stability of a Recombinant Fusion Protein Vaccine for Streptococcus pyogenes","volume":"19","author":"Burlet","year":"2017","journal-title":"AAPS J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1038\/s41598-017-07602-0","article-title":"Mucosal vaccination with pili from Group A Streptococcus expressed on Lactococcus lactis generates protective immune responses","volume":"7","author":"Loh","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ebiom.2017.05.030","article-title":"A Critical Role of Zinc Importer AdcABC in Group A Streptococcus-Host Interactions During Infection and Its Implications for Vaccine Development","volume":"21","author":"Makthal","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, N., Bi, S., Wang, X., and Wang, B. (2016). Co-Activation of Th17 and Antibody Responses Provides Efficient Protection against Mucosal Infection by Group A Streptococcus. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168861"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acsinfecdis.9b00347","article-title":"Group A Streptococcus Cell Wall Oligosaccharide-Streptococcal C5a Peptidase Conjugates as Effective Antibacterial Vaccines","volume":"6","author":"Wang","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Wang, G., Zhao, J., Zhao, Y., Wang, S., Feng, S., and Gu, G. (2021). Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020139"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e00618-16","DOI":"10.1128\/mBio.00618-16","article-title":"Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models","volume":"7","author":"Pandey","year":"2016","journal-title":"mBio"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e00122-20","DOI":"10.1128\/mBio.00122-20","article-title":"Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies","volume":"11","author":"Rhyme","year":"2020","journal-title":"mBio"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jinf.2016.02.002","article-title":"Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG","volume":"72","author":"Reglinski","year":"2016","journal-title":"J. Infect."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e02600-19","DOI":"10.1128\/mBio.02600-19","article-title":"A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes","volume":"10","author":"Bi","year":"2019","journal-title":"mBio"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/IM9.0000000000000044","article-title":"Site-Specific Conjugation of Cell Wall Polyrhamnose to Protein SpyAD Envisioning a Safe Universal Group A Streptococcal Vaccine","volume":"3","author":"Gao","year":"2010","journal-title":"Infect. Microbes Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/s41598-021-83673-4","article-title":"A multivalent T-antigen-based vaccine for Group A Streptococcus","volume":"11","author":"Loh","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1348-0421.12595","article-title":"Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus","volume":"62","author":"Wozniak","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.4049\/jimmunol.1700836","article-title":"Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen","volume":"199","author":"Nordstrom","year":"2017","journal-title":"J. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e03537-20","DOI":"10.1128\/mBio.03537-20","article-title":"Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF(R)01 Liposomes Induces Both Mucosal and Peripheral Protection from covR\/S Mutant Streptococcus pyogenes","volume":"12","author":"Ozberk","year":"2021","journal-title":"mBio"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41598-020-80508-6","article-title":"Preclinical safety and immunogenicity of Streptococcus pyogenes (Strep A) peptide vaccines","volume":"11","author":"Reynolds","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.actbio.2018.09.037","article-title":"Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against Group A Streptococcus","volume":"80","author":"Nevagi","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"eaax2285","DOI":"10.1126\/sciadv.aax2285","article-title":"Poly(amino acids) as a potent self-adjuvanting delivery system for peptide-based nanovaccines","volume":"6","author":"Skwarczynski","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/acs.jmedchem.0c01660","article-title":"Poly(hydrophobic amino acid)-Based Self-Adjuvanting Nanoparticles for Group A Streptococcus Vaccine Delivery","volume":"64","author":"Azuar","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1039\/D1BM01333E","article-title":"Physical mixture of a cyclic lipopeptide vaccine induced high titres of opsonic IgG antibodies against Group A Streptococcus","volume":"10","author":"Madge","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-020-00222-2","article-title":"M-protein based vaccine induces immunogenicity and protection from Streptococcus pyogenes when delivered on a high-density microarray patch (HD-MAP)","volume":"5","author":"Mills","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.4049\/jimmunol.1500157","article-title":"A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia","volume":"194","author":"Pandey","year":"2015","journal-title":"J. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.4049\/jimmunol.1501994","article-title":"Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR\/S Mutant Streptococci","volume":"196","author":"Pandey","year":"2016","journal-title":"J. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijpharm.2016.09.057","article-title":"Lipid core peptide\/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A Streptococcus","volume":"513","author":"Marasini","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.nano.2017.08.015","article-title":"Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection","volume":"13","author":"Schulze","year":"2017","journal-title":"Nanomedicine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jconrel.2019.11.018","article-title":"Semisynthetic, self-adjuvanting vaccine development: Efficient, site-specific sortase A-mediated conjugation of Toll-like receptor 2 ligand FSL-1 to recombinant protein antigens under native conditions and application to a model group A streptococcal vaccine","volume":"317","author":"Xu","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1586\/14760584.2015.1081817","article-title":"Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci","volume":"14","author":"Good","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1046\/j.1440-1711.2002.01067.x","article-title":"Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology","volume":"80","author":"Hayman","year":"2002","journal-title":"Immunol. Cell Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1016\/j.bmc.2014.09.042","article-title":"Self-adjuvanting vaccine against Group A Streptococcus: Application of fibrillized peptide and immunostimulatory lipid as adjuvant","volume":"22","author":"Azmi","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.292.6.709","article-title":"Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: Phase 1 trial","volume":"292","author":"Kotloff","year":"2004","journal-title":"JAMA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/cid\/ciad311","article-title":"Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring","volume":"77","author":"Asturias","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Sekuloski, S., Batzloff, M.R., Griffin, P., Parsonage, W., Elliott, S., Hartas, J., O\u2019Rourke, P., Marquart, L., Pandey, M., and Rubin, F.A. (2018). Evaluation of safety and immunogenicity of a Group A Streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198658"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41541-023-00609-x","article-title":"The Streptococcus pyogenes vaccine landscape","volume":"8","author":"Walkinshaw","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","article-title":"Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study","volume":"38","author":"Pastural","year":"2020","journal-title":"Vaccine"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41541-023-00730-x","article-title":"Update on the development of Group A Streptococcus vaccines","volume":"8","author":"Dorfmueller","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/QCO.0000000000000644","article-title":"Update on group A streptococcal vaccine development","volume":"33","author":"Dale","year":"2020","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/272\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:09:39Z","timestamp":1760105379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":135,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["vaccines12030272"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12030272","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}